SymBio Pharmaceuticals Limited (TYO:4582)

Japan flag Japan · Delayed Price · Currency is JPY
92.00
0.00 (0.00%)
Apr 28, 2026, 3:30 PM JST
-41.03%
Market Cap 6.60B
Revenue (ttm) 1.31B
Net Income (ttm) -4.78B
Shares Out 71.78M
EPS (ttm) -95.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 486,200
Average Volume 1,002,160
Open 92.00
Previous Close 92.00
Day's Range 91.00 - 94.00
52-Week Range 81.00 - 229.00
Beta 0.69
RSI 32.01
Earnings Date May 7, 2026

About SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan. [Read more]

Sector Healthcare
Founded 2005
Employees 91
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4582
Full Company Profile

Financial Performance

In 2025, SymBio Pharmaceuticals's revenue was 1.31 billion, a decrease of -46.70% compared to the previous year's 2.45 billion. Losses were -4.78 billion, 24.6% more than in 2024.

Financial Statements

News

There is no news available yet.